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Abstract
Epidemiology is the study of the distribution and determinants of
disease in human populations. Over the past decade there has
been considerable progress in our understanding of the
fundamental descriptive epidemiology (levels of disease frequency:
incidence and prevalence, comorbidity, mortality, trends over time,
geographic distributions, and clinical characteristics) of the
rheumatic diseases. This progress is reviewed for the following
major rheumatic diseases: rheumatoid arthritis (RA), juvenile
rheumatoid arthritis, psoriatic arthritis, osteoarthritis, systemic
lupus erythematosus, giant cell arteritis, polymyalgia rheumatica,
gout, Sjögren’s syndrome, and ankylosing spondylitis. These
findings demonstrate the dynamic nature of the incidence and
prevalence of these conditions - a reflection of the impact of
genetic and environmental factors. The past decade has also
brought new insights regarding the comorbidity associated with
rheumatic diseases. Strong evidence now shows that persons with
RA are at a high risk for developing several comorbid disorders,
that these conditions may have atypical features and thus may be
difficult to diagnose, and that persons with RA experience poorer
outcomes after comorbidity compared with the general population.
Taken together, these findings underscore the complexity of the
rheumatic diseases and highlight the key role of epidemiological
research in understanding these intriguing conditions.
Introduction
Epidemiology has taken an important role in improving our
understanding of the outcomes of rheumatoid arthritis (RA)
and other rheumatic diseases. Epidemiology is the study of
the distribution and determinants of disease in human
populations. This definition is based on two fundamental
assumptions. First, human disease does not occur at random;
and second, human disease has causal and preventive
factors that can be identified through systematic investigation
of different populations or subgroups of individuals within a
population in different places or at different times. Thus,
epidemiologic studies include simple descriptions of the
manner in which disease appears in a population (levels of
disease frequency: incidence and prevalence, comorbidity,
mortality, trends over time, geographic distributions, and
clinical characteristics) and studies that attempt to quantify
the roles played by putative risk factors for disease
occurrence. Over the past decade considerable progress has
been made in both types of epidemiologic studies. The latter
studies are the topic of Professor Silman’s review in this
special issue of Arthritis Research & Therapy [1]. In this
review we examine a decade of progress on the descriptive
epidemiology (incidence, prevalence, and survival) associated
with the major rheumatic diseases. We then discuss the
influence of comorbidity on the epidemiology of rheumatic
diseases, using RA as an example.
The epidemiology of rheumatoid arthritis
The most reliable estimates of incidence, prevalence, and
mortality in RA are those derived from population-based
studies [2-6]. Several of these, primarily from the past
decade, have been conducted in a variety of geographically
and ethnically diverse populations [7]. Indeed, a recent
systematic review of the incidence and prevalence of RA [8]
revealed substantial variation in incidence and prevalence
across the various studies and across time periods within the
studies. These data emphasize the dynamic nature of the
epidemiology of RA. A substantial decline in RA incidence
over time, with a shift toward a more elderly age of onset, was
a consistent finding across several studies. Also notable was
the virtual absence of epidemiologic data for the developing
countries of the world.
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Data from Rochester (Minnesota, USA) demonstrate that
although the incidence rate fell progressively over the four
decades of study - from 61.2/100,000 in 1955 to 1964, to
32.7/100,000 in 1985 to 1994 - there were indications of
cyclical trends over time (Figure 1) [9]. Moreover, data from
the past decade suggest that RA incidence (at least in
women) appears to be rising after four decades of decline
[10].
Several studies in the literature provide estimates of the
number of people with current disease (prevalence) in a
defined population. Although these studies suffer from a
number of methodological limitations, the remarkable finding
across these studies is the uniformity of RA prevalence rates
in developed populations - approximately 0.5% to 1% of the
adult population [11-18].
Mortality
Mortality, the ultimate outcome that may affect patients with
rheumatic diseases, has been positively associated with RA
and RA disease activity since 1953, although the physician
community has only recognized this link in recent years. Over
the past decade, research on mortality in RA and other
rheumatic diseases has gained momentum. These studies
have consistently demonstrated an increased mortality in
patients with RA when compared with expected rates in the
general population [9,13,19-23]. The standardized mortality
ratios varied from 1.28 to 2.98, with primary differences being
due to method of diagnosis, geographic location, demo-
graphics, study design (inception versus community cohorts),
thoroughness of follow up, and disease status [23-26].
Population-based studies specifically examining trends in
mortality over time have concluded that the excess mortality
associated with RA has remained unchanged over the past
two to three decades [19]. Although some referral-based
studies have reported an apparent improvement in survival, a
critical review indicated that these observations are likely due
to referral selection bias [26].
Recent studies have demonstrated that RA patients have not
experienced the same improvement in survival as the general
population, and therefore the mortality gap between RA
patients and individuals without RA has widened (Figure 2)
[25]. The reasons for this widening mortality gap are
unknown. Recent data (Figure 3) [27] suggest a trend toward
an increase in RA-associated mortality rates in the older
population groups.
Nonetheless, new treatments that dramatically reduce
disease activity and improve function should result in
improved survival. Since 2006, only methotrexate has shown
an effect on RA mortality, with a hazard ratio (HR) of 0.4
(95% confidence interval [CI] = 0.2 to 0.8), although lesser
powered studies have recently hinted at a similar effect of
anti-tumor necrosis factor (TNF) treatment [7,16,28,29].
A number of investigators have examined the underlying
causes for the observed excess mortality in RA [30]. These
reports suggest increased risk from cardiovascular, infec-
tious, hematologic, gastrointestinal, and respiratory diseases
among RA patients compared with control individuals.
Various disease severity and disease activity markers in RA
(for example, extra-articular manifestations, erythrocyte sedi-
mentation rate [ESR], seropositivity, higher joint count, and
functional status) have also been shown to be associated
with increased mortality [31-33].
The epidemiology of juvenile rheumatoid
arthritis
A number of studies have examined the epidemiology of
chronic arthritis in childhood [34-36]. Oen and Cheang [34]
conducted a comprehensive review of descriptive epidemio-
logy studies of chronic arthritis in childhood and analyzed
factors that may account for differences in the reported
incidence and prevalence rates. As this review illustrates, the
large majority of available studies are clinic-based and thus
are susceptible to numerous biases. The few population-
based estimates available indicate that the prevalence of
juvenile rheumatoid arthritis (JRA) is approximately 1 to 2 per
1,000 children, and the incidence is 11 to 14 new cases per
100,000 children.
The review by Oen and Cheang [34] revealed that reports of
the descriptive epidemiology of chronic arthritis in childhood
differ in methods of case ascertainment, data collection,
source population, geographic location, and ethnic back-
ground of the study population. This analysis further
demonstrated that the use of different diagnostic criteria had
no effect on the reported incidence or prevalence rates. The
Figure 1
Annual incidence of rheumatoid arthritis in Rochester, Minnesota.
Shown is the annual incidence rate per 100,000 population by sex:
1955 to 1995. Each rate was calculated as a 3-year centered moving
average. Reproduced from [9] with permission.strongest predictors of disease frequency were source
population (with the highest rates being reported in popu-
lation studies and the lowest in clinic-based cohorts) and
geographic origin of the report. The former is consistent with
more complete case ascertainment in population-based
studies compared with clinic-based studies, whereas the
latter suggests possible environmental and/or genetic influen-
ces in the etiology of juvenile chronic arthritis.
A review in 1999 [37] concurred that the variations in incidence
over time indicate environmental influences whereas ethnic and
familial aggregations suggest a role for genetic factors. The
genetic component of juvenile arthritis is complex, probably
involving the effects of multiple genes. The best evidence
pertains to certain human leukocyte antigen (HLA) loci (HLA-A,
HLA-DR/DQ, and HLA-DP), but there are marked differences
according to disease subtype [38,39]. Environmental influences
are also suggested by studies that demonstrated secular trends
in the yearly incidence of JRA, and a seasonal variation in
systemic JRA was documented [36,40-42].
Various studies examined long-term outcomes of JRA
[43-45]. Adults with a history of JRA have been shown to
have a lower life expectancy than members of the general
population of the same age and sex. Over 25 years of follow
up of a cohort of 57 adults with a history of RA [46], the
mortality rate among JRA cases was 0.27 deaths per 100
years of patient follow up, as compared with an expected
mortality rate of 0.068 deaths per 100 years of follow up in
the general population. All deaths were associated with
autoimmune disorders. In another study, a clinic-based cohort
of 215 juvenile idiopathic arthritis patients was followed up
for a median of 16.5 years [47]. The majority of the patients
had a favorable outcome and no deaths were observed. Half
of the patients had low levels of disease activity and few
physical signs of disease (for example, tender swollen joints,
restrictions in joint motion, and local growth disturbances).
Ocular involvement was the most common extra-articular
manifestation, affecting 14% of the patients.
The epidemiology of psoriatic arthritis
Five studies have provided data on the incidence of psoriatic
arthritis (PsA) [48-50]. Kaipiainen-Seppanen and Aho [51]
examined all patients who were entitled under the nationwide
sickness insurance scheme to receive specially reimbursed
medication for PsA in Finland in the years 1990 and 1995. A
total of 65 incident cases of PsA were identified in the 1990
study, resulting in an annual incidence of 6 per 100,000 of
the adult population aged 16 years or older. The mean age at
diagnosis was 46.8 years, with the peak incidence occurring
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Figure 2
Mortality in rheumatoid arthritis by sex. Observed mortality in (a) female
and (b) male patients with rheumatoid arthritis and expected mortality
(based on the Minnesota white population). Observed is solid line,
expected is dashed line, and the gray region represents the 95%
confidence limits for observed. Reproduced from [25] with permission.
Figure 3
Age-specific mortality in rheumatoid arthritis. Age-specific mortality
rates (per 100,000) for women with rheumatoid arthritis (death
certificates with any mention of rheumatoid arthritis). Reproduced from
[27] with permission.in the 45 to 54 year age group. There was a slight male to
female predominance (1.3:1). Incidence in 1995 was of the
same order of magnitude, at 6.8 per 100,000 (95% CI = 5.4
to 8.6). The incidence in southern Sweden was reported to
be similar to that in Finland [48].
A study by Shbeeb and coworkers [49] from Olmsted County
(Minnesota, USA) used the population-based data resources
of the Rochester Epidemiology Project to identify all cases of
inflammatory arthritis associated with a definite diagnosis of
psoriasis. Sixty-six cases of PsA were first diagnosed
between 1982 and 1991. The average age- and sex-adjusted
incidence rate per 100,000 was 6.59 (95% CI = 4.99 to
8.19), a rate remarkably similar to that reported in the Finnish
study [51]. The average age at diagnosis was 40.7 years. At
diagnosis 91% of cases had oligoarthritis. Over the
477.8 person-years of follow up, only 25 patients developed
extra-articular manifestations, and survival was not signifi-
cantly different from that in the general population. The preva-
lence rate on 1 January 1992 was 1 per 1,000 (95% CI =
0.81 to 1.21). The US study [49] reported a higher preva-
lence rate and lower disease severity than the other studies.
These differences may be accounted for by differences in the
case definition and ascertainment methods. Although the
Finnish cohort was population based, the ascertainment
methods in that study relied on receipt of medication for PsA.
Thus, mild cases not requiring medication may not have been
identified in the Finnish cohort.
Gladman and colleagues [52-54] have reported extensively
on the clinical characteristics, outcomes, and mortality
experiences of large groups of patients with PsA seen in a
single tertiary referral center. The results of these studies
differ from those of the population-based analyses in that they
demonstrate significantly increased mortality and morbidity
among patients with PsA compared with the general
population. However, because all patients in these studies
are referred to a single outpatient tertiary referral center,
these findings could represent selection referral bias. Clearly,
additional population-based data are needed to resolve these
discrepancies.
A recent population-based study of the incidence of PsA [55]
reported the overall age- and sex-adjusted annual incidence
of PsA per 100,000 to be 7.2 (95% CI = 6.0 to 8.4;
Figure 4). The incidence was higher in men (9.1, 95% CI =
7.1 to 11.0) than in women (5.4, 95% CI = 4.0 to 6.9). The
age- and sex-adjusted annual incidence of PsA per 100,000
increased from 3.6 (95% CI = 2.0 to 5.2) between 1970 and
1979, to 9.8 (95% CI = 7.7 to 11.9) between 1990 and
2000 (P for trend < 0.001), providing the first evidence that
the incidence of psoriasis increased during recent decades.
The point prevalence per 100,000 was 158 (95% CI = 132
to 185) in 2000, with a higher prevalence in men (193, 95%
CI = 150 to 237) than in women (127, 95% CI = 94 to 160).
The reasons for the increase remain unknown.
The epidemiology of osteoarthritis
Osteoarthritis (OA) is the most common form of arthritis,
affecting every population and ethnic group investigated thus
far. Although OA is most common in elderly populations,
reported prevalence values have a wide range because they
depend on the joint(s) involved (for example, knee, hip, and
hand) as well as the diagnosis used in the study (for instance,
radiographic, symptomatic, and clinical). Oliveria and
colleagues [56] illustrated this variation in symptomatic OA
incidence by sex and joint over time (Figure 5). Recently,
Murphy and coworkers [57] reported the lifetime risk for
symptomatic knee OA to be 44.7% (95% CI = 48.4% to
65.2%). Increasing age, female sex, and obesity are primary
risk factors for developing OA.
OA accounts for more dependency in walking, stair climbing,
and other lower extremity tasks than any other disease [58].
Recently, Lawrence and colleagues [59] estimated that 26.9
million Americans aged 25 or older had clinical OA of some
joint. The economic impact of OA, both in terms of direct
medical costs and lost wages, is impressive [60,61]. In 2005,
hospitalizations for musculoskeletal procedures in the USA,
which were predominantly knee arthroplasties and hip
replacements, totaled $31.5 billion or more than 10% of all
hospital care [62]. This highlights the dramatic increase in
societal costs and burden of OA, because only 10 years
earlier the entire cost of OA in the USA was estimated at
$15.5 billion dollars (1994 dollars) [63]. Given that
preventive interventions and therapeutic options for OA are
limited, we can expect the morbidity and economic impact of
OA to increase with the aging of the developed world.
Arthritis Research & Therapy    Vol 11 No 3 Gabriel and Michaud
Page 4 of 16
(page number not for citation purposes)
Figure 4
Annual incidence of psoriatic arthritis by age and sex. Shown is the
annual incidence (per 100,000) of psoriatic arthritis by age and sex
(1 January 1970 to 31 December 1999; Olmsted County, Minnesota).
Broken lines represent smoothed incidence curves obtained using
smoothing splines. Reproduced from [55] with permission.The epidemiology of systemic lupus
erythematosus
A population-based study examined the incidence and
mortality of systemic lupus erythematosus (SLE) in a
geographically defined population over a 42-year period [64].
These findings indicate that, over the past 4 decades, the
incidence of SLE has nearly tripled and that the survival rate
for individuals with this condition (while still poorer than
expected for the general population) has significantly im-
proved. The average incidence rate (age- and sex-adjusted to
the 1970 US white population) was 5.56 per 100,000 (95%
CI = 3.93 to 7.19) during the period from 1980 to 1992, as
compared with an incidence of 1.51 (95% CI = 0.85 to 2.17)
during the period from 1950 to 1979. These results compare
favorably with previously reported SLE incidence rates of
between 1.5 and 7.6 per 100,000. In general, studies
reporting higher incidence rates utilized more comprehensive
case retrieval methods. The reported prevalence of SLE has
also varied significantly. One study reported an age- and sex-
adjusted prevalence, as of 1 January 1992, of approximately
122 per 100,000 (95% CI = 97 to 147) [64]. This
prevalence is higher than other reported prevalence rates in
the continental USA, which have ranged between 14.6 and
50.8 per 100,000 [65]. However, two studies of self-reported
diagnoses of SLE indicated that the actual prevalence of SLE
in the USA may be much higher than previously reported
[66]. One of these studies validated the self-reported
diagnoses of SLE by reviewing available medical records
[66], revealing a prevalence of 124 cases per 100,000.
There is good evidence that survival in SLE patients has
improved significantly over the past four decades [67].
Explanations for the improved survival included earlier diag-
nosis of SLE, recognition of mild disease, increased utilization
of anti-nuclear antibody testing, and better approaches to
therapy. Walsh and DeChello [68] demonstrated con-
siderable geographic variation in SLE mortality within the
USA. Although it is difficult to distinguish between whether
the observed variation reflects clustering of risk factors for
SLE or regional differences in diagnosis and treatment, there
is a clear pattern of elevated mortality in clusters with high
poverty rates and greater concentrations of ethnic Hispanic
patients versus those with lower mortality. Moreover, although
improvements in survival have also been demonstrated in
some Asian and African countries, these are not as significant
as in the USA [69,70].
The epidemiology of giant cell arteritis and
polymyalgia rheumatica
Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA)
are closely related conditions [71]. Numerous studies have
been conducted that describe the epidemiology of PMR and
GCA in a variety of population groups. As shown in Additional
file 1, GCA appears to be most frequent in the Scandinavian
countries, with an incidence rate of approximately 27 per
100,000 [72] and in the northern USA, with an incidence rate
of approximately 19 per 100,000 [73], as compared with
southern Europe and the southern USA, where the reported
incidence rates have been approximately 7 per 100,000. Such
remarkable differences in incidence rates according to
geographic variation and latitude are suggestive of a common
environmental exposure. Nonetheless, these differences do
not rule out common genetic predisposition.
The average annual age- and sex-adjusted incidence of PMR
per 100,000 population aged 50 years or older has been
estimated at 58.7 (95% CI = 52.8 to 64.7), with a signifi-
cantly higher incidence in women (69.8; 95% CI = 61.2 to
78.4) than in men (44.8; 95% CI = 37.0 to 52.6) [74]. The
prevalence of PMR among persons older then 50 years on
1 January 1992 has been estimated at 6 per 1,000. The
incidence rate in Olmsted County (58.7/100,000) is similar
to that reported in a Danish County (68.3 per 100,000), but
is somewhat higher than that reported in Goteborg, Sweden
(28.6/100,000), in Reggio Emilia, Italy (12.7/100,000) and
Lugo, Spain (18.7/100,000) [75].
Secular trends in incidence rates can provide important
etiologic clues. Two studies have examined secular trends in
the incidence of GCA/PMR. Nordborg and Bengtsson [76]
from Goteberg, Sweden, examined trends in the incidence of
GCA between 1977 and 1986, and showed a near doubling
of the incidence rate over this time period, particularly in
females. Data from Olmsted County have also shown
important secular trends in the incidence of GCA [73]. The
annual incidence rates increased significantly from 1970 to
2000 and appeared to have clustered in five peak periods,
which occurred about every 7 years. A significant calendar-time
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Figure 5
Incidence of osteoarthritis by joint. Shown is the incidence of
osteoarthritis of the hand, hip, and knee in members of the Fallon
Community Health Plan, 1991 to 1992, by age and sex. Reproduced
from [56] with permission.effect was identified, which predicted an increase in incidence
of 2.6% (95% CI = 0.9% to 4.3%) every 5 years [73]. Similarly,
Machado and coworkers [77] demonstrated an increase in
incidence rates between 1950 and 1985. Notably, these
secular trends were quite different in women, in whom the rate
increased steadily over the time period, as compared with men,
in whom the rate increased steadily from 1950 to 1974 and
then began to decline during the late 1970s and early 1980s.
The same finding of different secular trends, according to sex,
were also observed in the Swedish study [76].
Such secular trends may be the result of increased
recognition of that disease. In fact, there have been reports
demonstrating that the observed frequency of classic disease
manifestations in patients with a subsequent diagnosis of
GCA is actually declining. This suggests that awareness of
the less typical manifestations has improved, resulting in the
diagnosis of previously unrecognized cases. However, if
improved diagnosis were the only factor accounting for the
increase in incidence rate, then comparable changes in both
sexes would have been expected. This was not so.
The epidemiology of gout
Until relatively recently there have been very few studies on
the epidemiology of gout. In 1967, a study using the Framing-
ham data reported the prevalence of gout at 1.5% (2.8% in
men and 0.4% in women) [78]. In England, Currie [79]
reported the prevalence of gout to be 0.26% in 1975, and a
multicenter study [80] reported the prevalence to be 0.95%
in 1995. Various studies revealed that both gout and hyper-
uricemia have been increasing in the USA, Finland, New
Zealand, and Taiwan [81-84]. The most recent study of the
incidence of gout was a longitudinal cohort study of 1,337
eligible medical students who received a standardized
medical examination and questionnaire during medical school
[85]. Sixty cases (47 primary and 13 secondary) were
identified among the 1,216 men included in the study. None
occurred among the 121 women in the study. The cumulative
incidence of all gout was 8.6% among men (95% CI = 5.9%
to 11.3%). Body mass index at age 35 years (P = 0.01),
excessive weight gain (>1.88 kg/m2) between cohort entry
and age 35 years (P = 0.007), and the development of
hypertension (P = 0.004) were significant risk factors for the
development of gout in univariate analyses. Multivariate Cox
proportional hazards models confirmed the association of
body mass index at age 35 years (relative risk [RR] = 1.12;
P = 0.02), excessive weight gain (RR = 2.07; P = 0.02), and
hypertension (RR = 3.26; P = 0.002) as risk factors for all
gout. Recent studies have reported the prevalence of gout in
the UK and Germany to be 1.4% during the years 2000 to
2005, and highlight the importance of comorbidities (obesity,
cardiovascular disease, diabetes, and hypertension) [86,87]
The epidemiology of Sjögren’s syndrome
There have been very few studies performed describing the
epidemiology of Sjögren’s syndrome and keratoconjunctivitis
sicca. Moreover, interpretation of existing studies is compli-
cated by differences in the definition and application of
diagnostic criteria. In a population-based study from Olmsted
County, Minnesota, the average annual age- and sex-adjusted
incidence of physician-diagnosed Sjögren’s syndrome per
100,000 population was estimated to be 3.9 (95% CI = 2.8 to
4.9), with a significantly higher incidence in women (6.9; 95%
CI = 5.0 to 8.8) than in men (0.5; 95% CI = 0.0 to 1.2) [88].
The prevalence of dry eyes or dry mouth and of primary
Sjögren’s syndrome among 52- to 72-year-old residents of
Malmo, Sweden, according to the Copenhagen criteria, were
established in 705 randomly selected individuals who
answered a simple questionnaire. The calculated prevalence
for the population of keratoconjunctivitis sicca was 14.9%
(95% CI = 7.3% to 22.2%), of xerostomia 5.5% (95% CI =
3.0% to 7.9%), and of autoimmune sialoadenitis and primary
Sjögren’s syndrome 2.7% (95% CI = 1.0% to 4.5%). The
Hordaland Health Study in Norway reported that the
prevalence of primary Sjögren’s syndrome was approximately
seven times higher in the elderly population (age 71 to
74 years) compared with individuals aged 40 to 44 years
[89]. In a Danish study, the frequency of keratoconjunctivitis
sicca in persons age 30 to 60 years was estimated at 11%,
according to the Copenhagen criteria, and the frequency of
Sjögren’s syndrome in the same age group was estimated to
be between 0.2% and 0.8% [90]. In another study from
China [91], the prevalence was 0.77% using Copenhagen
criteria and 0.33% using the San Diego criteria. Two studies
from Greece and Slovenia reported prevalences of 0.1% and
0.6%, respectively [92], whereas a Turkish study estimated
the prevalence of Sjögren’s syndrome at 1.56% [93,94].
Sjögren’s syndrome has also been reported to be associated
with other rheumatic and autoimmune conditions, including
fibromyalgia, autoimmune thyroid disease, multiple sclerosis,
and spondyloarthropathy, as well as several malignancies,
especially non-Hodgkin lymphoma.
The epidemiology of ankylosing spondylitis
Two large population-based studies provided estimates of
the incidence and prevalence of ankylosing spondylitis
[95,96]. Using the population-based data resources of the
Rochester Epidemiology Project, Carbone and coworkers
[95] determined the incidence and prevalence of ankylosing
spondylitis first diagnosed between 1935 and 1989 among
residents of Rochester. The overall age- and sex-adjusted
incidence was 7.3 per 100,000 person years (95% CI = 6.1
to 8.4). This incidence rate tended to decline between 1935
and 1989; however, there was little change in the age at
symptom onset or at diagnosis over the 55-year study period.
Overall survival was not decreased up to 28 years after
diagnosis. Using the population-based data resources of the
Finland sickness insurance registry, Kaipiainen-Seppanen
and coworkers [51,96] estimated the annual incidence of
ankylosing spondylitis requiring antirheumatic medication to
be 6.9 per 100,000 adults (95% CI = 6.0 to 7.8) with no
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(95% CI = 0.08% to 0.27%). Together, these findings indi-
cate that there is constancy in the epidemiologic charac-
teristics of ankylosing spondylitis.
The incidence and prevalence of ankylosing spondylitis has
also been studied in various populations. The incidence of
ankylosing spondylitis was shown to be relatively stable in
northern Norway over 34 years at 7.26 per 100,000 [97].
Prevalence varied from 0.036% to 0.10%. In Greece and
Japan, the incidence and prevalence of ankylosing spondylitis
were significantly lower [98-101]. The incidence mirrors the
prevalence of HLA-B27 seropositivity. HLA-B27 is present
throughout Eurasia, but is virtually absent among the genetic
unmixed native populations of South America, Australia, and
in certain regions of equatorial and southern Africa. It has a
very high prevalence among the native peoples of the
circumpolar arctic and the subarctic regions of Eurasia and
North America and in some regions of Melanesia. The
prevalence of ankylosing spondylitis and the spondyloarthro-
pathies is known to be very high in certain North American
Indian populations [102,103].
The role of comorbidity in determining
outcome in the rheumatic diseases: the
example of rheumatoid arthritis
What is comorbidity and why is it important?
A comorbid condition is a medical condition that co-exists
along with the disease of interest, for example RA.
Comorbidity can be further defined in terms of a current or
past condition. It may represent an active, past, or transient
illness. It may be linked to the rheumatic disease process
itself and/or its treatment, or it may be completely
independent of these (Table 1).
Because of these links, comorbidities have grown in
importance to physicians and researchers because they
greatly influence the patient’s quality of life, the effectiveness
of treatment, and the prognosis of the primary disease. The
average RA patient has approximately 1.6 comorbidities
[104], and the number increases with the patient’s age. As
may be expected, the more comorbidities a patient has, the
greater the utilization of health services, the greater societal
and personal costs, the poorer the quality of life, and the
greater chances of hospitalization and mortality. Moreover,
comorbidity adds considerable complexity to patient care,
making diagnosis and treatment decisions more challenging.
For example, myocardial infarction (MI) is much more likely to
be silent among persons with diabetes mellitus or RA, than in
the absence of those comorbidities. The outcome of MI or
heart failure is worse among individuals with RA or diabetes
mellitus. In addition, the more comorbid illnesses one has, the
greater the interference with treatment and the greater the
medical costs, disability, and risk for mortality. Therefore, it is
important to recognize such illnesses and to account for them
in the care of the individual patient.
RA outcomes include mortality, hospitalization, work dis-
ability, medical costs, quality of life, and happiness, among
others. Different comorbid conditions influence such out-
comes differently [105]. For example, pulmonary and cardiac
comorbidity are most often associated with mortality, but
work disability is more strongly associated with depression.
Therefore, when we speak of comorbidity and its effect on
prognosis, we need to define which outcome is of greatest
interest.
Current interest in comorbidity also springs from the desire to
understand causal pathological associations. For example,
the documentation that cardiovascular diseases are
increased in persons with RA, after controlling for cardiac risk
factors [106], provides a basis for the understanding of the
effect of RA inflammation on cardiac disease.
Comorbidity in rheumatoid arthritis
Cardiovascular diseases
Much recent literature has demonstrated that the excess
mortality in persons with RA is largely attributable to
cardiovascular disease [107]. The most common cardio-
vascular disease is ischemic heart disease. Research has
repeatedly demonstrated that the risk for ischemic heart
disease is significantly higher among persons with RA than in
control individuals [108-115]. A recent population-based
study of RA and comparable non-RA subjects showed that
those with RA are at a 3.17-fold higher risk for having had a
hospital MI (multivariable odds ratio = 3.17, 95% CI = 1.16
to 8.68) and a nearly 6-fold increased risk for having had a
silent MI (multivariable odds ratio = 5.86, 95% CI = 1.29 to
26.64) [108]. These data also demonstrated that the cumula-
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Table 1
Examples of comorbid conditions by their relationship with
rheumatoid arthritis
Estimated 
relationship Comorbid  Mechanism  of 
to RA  condition relationship
High Anemia RA activity
Osteoporosis CS, RA, decreased function
Bacterial infection RA, CS, smoking, (TNF?)
Medium Lymphoma RA activity, (TNF?)
GI ulceration NSAIDs, CS
Myocardial infarction RA, CS
Heart failure RA, CS
Low Stroke RA
Depression Chronic pain
Fracture CS, decreased function
Skin cancer RA, TNF
Any cancer
No relationship Appendicitis
CS, corticoid steroid treatment, GI, gastrointestinal; NSAID = Non-
steroidal anti-inflammatory drug treatment; RA, rheumatoid arthritis;
TNF, antitumor necrosis factor treatment.tive incidence of silent MI and of sudden death after incidence/
index date continue to rise over time (Figures 6 and 7).
In contradistinction, the same study reported that both the
prevalence of angina pectoris at incidence/index date as well
as the cumulative risk for angina pectoris after 30 years of
follow up are significantly lower in persons with RA compared
with the general population [108].
An emerging body of literature now indicates that persons
with RA are also at increased risk for heart failure. The
cumulative incidence of heart failure defined according to
Framingham Heart Study criteria [116] after incident RA has
been shown to be statistically significantly higher in persons
with RA than in those without the disease in a population-
based setting [117] (Figure 8).
At any particular age, the incidence of heart failure in RA
patients was approximately twice that in non-RA individuals.
Data from multivariable Cox models showed that RA subjects
had about twice the risk for developing heart failure and that
this risk changed little after accounting for the presence of
ischemic heart disease, other risk factors, and the combi-
nation of these [117].
In subset analyses, this risk appeared to be largely confined
to rheumatoid factor-positive RA cases. Indeed, rheumatoid
factor-positive RA patients had a risk for developing heart
failure that was 2.5 times higher than that in non-RA
individuals - an excess risk very similar to that experienced by
persons with diabetes mellitus.
Davis and colleagues [118] examined the presentation of
heart failure in RA compared with that in the general popula-
tion. They reported that RA patients with heart failure
presented with a different constellation of signs and
symptoms than non-RA individuals with heart failure. In
particular, RA patients with heart failure were less likely to be
obese or hypertensive, or to have had a history of ischemic
heart disease. Moreover, the proportion of RA patients with
heart failure with preserved ejection fraction (≥50%) was
significantly higher compared with non-RA individuals with
heart failure (58.3% versus 41.4%; P = 0.02). Mean ejection
fraction was also shown to be higher among RA patients than
in non-RA individuals (50% versus 43%, P = 0.007).
Indeed, the likelihood of preserved ejection fraction at the
onset of heart failure was 2.57 times greater in heart failure
patients with RA than in those without RA (odds ratio = 2.57,
95% CI = 1.20 to 5.49). Other investigators also reported
that heart failure is more common in persons with RA, and a
number of echocardiographic series have reported preserved
ejection fraction and/or diastolic functional impairment in
persons with RA [119-121].
In summary, persons with RA appear to have an increased
risk of both ischemic heart disease and heart failure. These
comorbid conditions may present in an atypical fashion,
making diagnosis and management challenging.
Malignancy
After cardiovascular disease, cancer is the second most
common cause of mortality in RA patients. Figure 9 shows
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Figure 6
Incidence of silent myocardial infarction: RA versus non-RA. Shown is
the cumulative incidence of silent myocardial infarction in a population-
based incidence cohort of 603 RA patients and a matched non-RA
comparison group of 603 non-RA individuals from the same underlying
population. Reproduced from [108] with permission.
Figure 7
Incidence of sudden cardiac death: RA versus non-RA. Shown is the
cumulative incidence of sudden cardiac death in a population-based
incidence cohort of 603 rheumatoid arthritis (RA) patients and a
matched non-RA comparison group from the same underlying
population. Reproduced from [108] with permission.the standardized incidence rates (SIRs) from 13 recent
studies during the past decade in a meta-analysis [122]. The
overall SIR of nonskin cancer malignancy in RA is estimated
to be 1.05 (95% CI = 1.01 to 1.09). Although the risk
appears to be slightly increased in persons with RA, this
increase appears to be due to only a few specific
malignancies: lymphoma, lung cancer, and skin cancer. It is
also possible that some cancers may actually have a
decreased risk.
Baeckland and coworkers [123] showed that lymphoma is
not only increased in RA but also is related to the severity of
the disease itself. Combining six recent studies, the analysis
reported by Smitten and coworkers [122] determined the SIR
of lymphoma to be 2.08 (95% CI = 1.80 to 2.39) in RA.
Recent research has linked smoking exposure to increased
incidence of developing RA [124,125]. After examining 12
recent studies, Smitten and coworkers [122] reported an SIR
of 1.63 (95% CI = 1.43 to 1.87) for lung cancer in RA. This
increase in lung cancer is probably related, at least in part, to
the excess risk for smoking related to RA [126].
After lung cancer, breast cancer is the second most common
cause of cancer among RA patients. Most studies show rates
of breast cancer to be decreased among RA patients.
Smitten and coworkers [122] summarized nine recent studies
with an estimated SIR of 0.84 (95% CI = 0.79 to 0.90). The
mechanism for this reduction is not understood, although
James [127] hypothesizes that estrogen changes in RA may
be a factor.
The risk for colorectal cancer has also been reported to be
decreased in RA, with Smitten and coworkers [122] report-
ing an SIR of 0.77 (95% CI = 0.65 to 0.90) based on data
summarized from 10 studies. This effect is hypothesized to
be a result of the prostaglandin production due to the high
use of nonsteroidal anti-inflammatory drugs (NSAIDs) and
cyclo-oxygenase (COX)-2 selective inhibitors in RA patients.
Because skin cancer is relatively common and is often
misdiagnosed, it has been difficult to determine the effect of
RA on development of this cancer. Chakravarty and co-
workers [128] identified an association between RA and
nonmelanoma skin cancer, and Wolfe and Michaud [129]
found an association between RA biologic treatment with an
increased risk of nonmelanoma skin cancer (odds ratio = 1.5,
95% CI = 1.2 to 2.8) and melanoma (odds ratio = 2.3, 95%
CI = 0.9 to 5.4).
Lung disease
Pulmonary infection is a major cause of death in RA.
Infections may arise de novo, as in people without RA, or it
might be facilitated by impaired immunity or underlying
interstitial lung disease (ILD). The rate of ILD in RA varies with
the method of ascertainment, and prospective studies have
reported prevalence values ranging from 19% to 44% [130].
The prevalence of lung fibrosis and ‘RA lung’, as reported to
patients by their physicians, has been estimated at 3.3%
[131]. This estimate is in line with the 1% to 5% rate reported
on chest radiographs among RA patients [130]. When
assessed in 150 unselected consecutive patients with RA by
high-resolution computed tomography, however, 19% were
found to have fibrosing alveolitis [130]. These authors noted
that if other prospective studies of ILD were combined using
a common definition, the average prevalence would be 37%
[132-134]. Many cases of ILD remain undetected or may be
mild or even asymptomatic. However, once patients are
symptomatic with ILD, there is a high mortality rate
[135,136]. ILD in RA may be different from ‘usual’ ILD,
including differences in CD20+ B-cell infiltrates that imply ‘a
differential emphasis of B cell-mediated mechanisms’.
Computed tomography findings also differ for RA and non-RA
ILD [137].
The cause of ILD in persons with RA is not known. However,
almost all disease-modifying antirheumatic drugs have been
linked to lung disease and/or ILD, including injectable gold,
penicillamine [138,139], sulfasalazine [140], methotrexate
[141-143], infliximab [144,145], and leflunomide [146], with
some reports linking infliximab to rapidly progressive and/or
fatal ILD [147,148].
Infection
Like other inflammatory disorders, RA appears to increase the
risk for bacterial, tubercular, fungal, opportunistic, and viral
infections, with all infections being more common in more
active and severe RA [149]. The use of corticosteroids, and
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Figure 8
Incidence of congestive heart failure: RA versus non-RA. Shown is a
comparison of the cumulative incidence of congestive heart failure in
the rheumatoid arthritis (RA) and non-RA cohort, according to years
since index date, adjusting for the competing risk for death.
Reproduced from [117] with permission.in some studies anti-TNF therapy, increases the risk for
infection [150,151]. In nonrandomized trials and observa-
tional studies, patients with severe RA are more likely to
receive these therapies, thereby confounding the effect of RA
and RA treatment. This channeling bias might explain a
proportion of the observed increase in infections.
Before the methotrexate and anti-TNF era, studies showed a
general increase in mortality due to infection in RA patients
[152-155]. In a recent study from an inception cohort of
2,108 patients with inflammatory polyarthritis from a
community-based registry followed up annually (median
9.2 years), the incidence of infection was more than two and
a half times that of the general population. History of smoking,
corticosteroid use, and rheumatoid factor were found to be
significant independent predictors of infection-related hos-
pitalization [156].
Corticosteroid use is associated with increased risk of
serious bacterial infection [150,151,156-159]. The data with
regard to anti-TNF therapy and infection is complex. Results
of randomized trials indicate increased risk for infection
[144,160]. In addition, some studies show increased risk in
the community associated with anti-TNF therapy [159],
whereas other studies do not [151,158,161]. Among 2,393
RA patients followed in an administrative database, the
multivariable-adjusted risk for hospitalization with a physician-
confirmed definite bacterial infection was approximately
twofold higher overall and fourfold higher during the first
6 months among patients receiving TNF-α antagonists versus
those receiving methotrexate alone [159]. However, RA-
based cohorts show no such increase, although some have
reported an early increase in infection rate followed by a later
decrease [151,158,161].
Tuberculosis (TB) appears to be increased in RA patients
independent of treatment [162-167], although one US study
differed in this regard [168]. Anti-TNF therapy substantially
increases the risk for TB, notably in patients treated with
infliximab [164-169]. Use of prednisone in doses of less than
15 mg/day was associated with an odds ratio for TB of 2.8
(95% CI = 1.0 to 7.9) in the UK General Practice Research
Database [170]. Even with chemoprophylaxis, patients
remain at high risk for developing active TB [171,172].
There are few data with respect to viral infections. In general,
there is an increased risk of herpes zoster in RA patients
[173]. However, this risk is not increased in RA relative to
OA, and is strongly linked to functional status as measured by
the Health Assessment Questionnaire (HR = 1.3 in both
groups) [174]. In this study, cyclophosphamide (HR = 4.2),
azathioprine (HR = 2.0), prednisone (HR = 1.5), leflunomide
(HR = 1.4), and COX-2 selective NSAIDs (HR = 1.3) were all
significant predictors of herpes zoster risk [174] Controlling
for RA severity, there appears no significant increased risk for
herpes zoster due to methotrexate or general anti-TNF
therapy [174,175], but there is new evidence of an effect due
to monoclonal anti-TNFs (HR = 1.82) [175].
Gastrointestinal ulcer disease
Although increased in RA, there is currently no evidence to
indicate that gastrointestinal ulcers are due to a specific RA
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Figure 9
Relative risks for overall malignancies in RA patients versus general population. *Excluding nonmelanoma skin. †All solid tumors. ‡Excluding
lymphatic and hematopoietic. CI, confidence interval; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; n, number of
malignancies; N, population size; SIR, standardized incidence ratio; TNF, tumor necrosis factor. For original references see Smitten and coworkers
[122].process, but there is evidence that they are due to commonly
used therapies in RA. Many studies have reportedly demon-
strated the association of NSAIDs with gastrointestinal
ulceration and the reduction in ulceration rates with COX-2
and gastrointestinal prophylactic agents [176-182]. The risk
for gastrointestinal ulceration is also associated with cortico-
steroid use and increased further by concomitant NSAID
usage in the UK General Practice Research Database [183].
Other risk factors for gastrointestinal ulceration, based on
clinical trial and observational data in RA, include impaired
functional status, older age, and previous ulceration.
Other: anemia, osteoporosis, and depression
Using the World Health Organization definition of anemia
(hemoglobin <12 g/dl for women and <13 g/dl for men),
anemia occurs in 31.5% of RA patients. After erythrocyte
sedimentation rate, C-reactive protein is the strongest pre-
dictor of anemia, followed by estimated creatinine clearance.
Severe chronic anemia (hemoglobin <10 g/dl) is rare in RA
(3.4%). Overall, the rate of anemia is threefold higher in RA
patients than in the general population [184].
Osteopenia is a consequence of RA, decreased physical
activity, and treatment with corticosteroids [185-188]. In 394
female RA patients included in the Oslo County Rheumatoid
Arthritis Register, a twofold increase in osteoporosis was
reported compared with the general population [185].
Fractures resulting from osteoporosis rank highly among
comorbidities contributing to mortality, future hospitalizations,
and increased disability. The rate of fracture is increased
twofold among persons with RA. Following 30,262 RA
patients in the General Practice Research Database, van
Staa and coworkers [186] found a RR for hip fracture of 2.0
(95% CI = 1.8 to 2.3) and spine fracture of 2.4 (95% CI =
2.0 to 2.8) compared with non-RA control individuals. Osteo-
porosis is increased in RA independent of corticosteroid
usage [186-188]. Van Staa and coworkers [186] found the
RR for an osteoporotic fracture in RA patients with no recent
corticosteroid usage to be 1.2 (95% CI = 1.1 to 2.3),
although this risk was more than doubled with recent cortico-
steroid use, even when used in low doses [185,186,189].
Despite the numerous reports and serious nature of osteo-
porosis, preventive care provided by rheumatologists is sub-
optimal [190] (assessing the need for additional protective
therapies including bisphosphonates and parathyroid hor-
mone, monitoring bone mass by dual-energy X-ray absorptio-
metry, and providing calcium and vitamin D supplementation).
Depression is concomitant with virtually all chronic illnesses
and is not increased in RA compared with those with other
chronic illnesses [191]. Evidence suggests that depression
leads to increased mortality in persons with RA [192].
Outcome after comorbidity in rheumatoid arthritis
Not only do persons with RA appear to be at increased risk
for a number of important comorbidities, but outcome after
comorbidities has also been shown to be poorer in persons
with RA compared with the general population. Mortality after
MI has been shown to be significantly higher in MI cases with
RA than in MI cases who do not have RA (HR for mortality in
RA versus non-RA: 1.46, 95% CI = 1.01 to 2.10; adjusted
for age, sex, and calendar year) [118]. Likewise, 6-month
mortality after heart failure was significantly worse in heart
failure cases with RA versus those without (Figure 10) [118].
The risk for mortality at 30 days after heart failure was 2.57-
fold higher for RA patients than for non-RA individuals after
adjusting for age, sex, and calendar year, whereas the risk of
mortality at 6 months after heart failure was 1.94-fold higher
for RA patients compared to non-RA individuals after similar
adjustment. These comparisons were both highly statistically
significant.
There is strong evidence that persons with RA are at high risk
for developing several comorbid disorders. Comorbid
conditions in persons with RA may have atypical features and
thus may be difficult to diagnose. There is no evidence that
the excess risks for these comorbidities have declined.
Emerging evidence points to poorer outcomes after
comorbidity in persons with RA compared with the general
population.
Conclusions
The past decade has brought many new insights regarding
the epidemiology and comorbidity of the rheumatic diseases.
It has been demonstrated that the incidence and prevalence
of these conditions is dynamic, not static, and appears to be
influenced by both genetic and environmental factors. There
is strong evidence that persons with RA are at high risk for
developing several comorbid disorders. Comorbid conditions
in persons with RA may have atypical features and thus may
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Figure 10
Twelve-month mortality after heart failure. Reproduced from [118] with
permission.be difficult to diagnose. There is no evidence that the excess
risks of these comorbidities have declined. Emerging
evidence points to poorer outcomes after comorbidity in
persons with RA compared with the general population.
Taken together these findings underscore the complexity of
the rheumatic diseases and highlight the key role of
epidemiological research in understanding these intriguing
conditions.
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